Grace Therapeutics (GRCE) Other financing activities (2019 - 2025)
Grace Therapeutics' (GRCE) quarterly Other financing activities came in at $241000.0 in Q4 2025, up 502.5% quarter-over-quarter from $40000.0 in Q1 2021.
Powered by 
Analysis
Grace Therapeutics (GRCE) Other financing activities (2019 - 2025) Analysis & Trends
Grace Therapeutics has disclosed Other financing activities across 4 years of filings, most recently posting $241000.0 for Q4 2025.
- In Q4 2025, Other financing activities changed N/A year-over-year to $241000.0; the TTM figure through Mar 2026 stood at $241000.0 (changed N/A YoY), while the FY2026 annual figure was $4.0 million, changed N/A from the prior year.
- Other financing activities came in at $241000.0 for Q4 2025 at Grace Therapeutics, up from $40000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $241000.0 in Q4 2025 to a low of $40000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.01 Bn | 621.25 Bn | 17.26 Bn |
| 2 | AbbVie | 446.87 Bn | 440.30 Bn | 12.70 Bn |
| 3 | Merck | 358.09 Bn | 350.95 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.67 Bn | 259.98 Bn | 11.24 Bn |
| 5 | Pfizer | 156.85 Bn | 145.15 Bn | 10.94 Bn |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.11 Bn | 43.11 Bn | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn |
| 10 | Grace Therapeutics | 39.38 Mn | 39.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 241,000.00 |
| Mar 31, 2021 | 40,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Mar 31, 2020 | -27,000.00 |
| Dec 31, 2019 | 1.08 Mn |
| Sep 30, 2019 | 6.62 Mn |
| Jun 30, 2019 | 34,000.00 |